The INSULIN Act of 2026: Proposed Changes to Insulin Costs and Access
June 24, 2026
Track this bill to get notified when it advances a stage. One tap to stop, anytime.
The Frame
If enacted, this legislation would cap monthly out-of-pocket insulin costs at $35 for most insured patients starting in 2027 and authorize $100 million in grants to help states provide affordable insulin to uninsured residents.
Potentially affected actors named in the source documents. Mention is not a position.
Insured patients
Patients with group or individual health insurance would see their out-of-pocket costs for selected insulin products capped at $35 per month.
Uninsured individuals
Individuals without insurance would gain access to state-run assistance programs and a national resource center for finding affordable insulin.
Pharmacy benefit managers
These entities must remit 100% of insulin-related rebates and fees to health plans and are prohibited from imposing certain medical management requirements on insulin.
Health insurance issuers
Issuers must provide coverage for selected insulin products without deductibles and comply with new cost-sharing limits.
Last recorded activity June 24, 2026.
Next step not available in the current record.
Background
- Mrs. Shaheen, Ms. Collins, Mr. Warnock, and Mr. Kennedy are U.S. Senators who frequently collaborate on bipartisan healthcare legislation. context
- This amendment is attached to S. 4784, a larger defense authorization bill, a common legislative vehicle for unrelated policy riders. context
Summary
Why It Matters
If enacted, this legislation would cap monthly out-of-pocket insulin costs at $35 for most insured patients starting in 2027 and authorize $100 million in grants to help states provide affordable insulin to uninsured residents.
Key Facts
You don't have to trust us. Each fact below is taken straight from the official document - click any one to see the exact passage, highlighted in the original.
Frequently Asked Questions
Will my insulin costs go down if this passes?
What if I don't have health insurance?
Does this affect how pharmacy benefit managers operate?
News Coverage
Sponsors
Discoveries
Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.
Anti-Delay Measures
The bill introduces strict timelines and FTC referral procedures for citizen petitions, signaling a legislative effort to curb the use of administrative filings to delay generic drug competition.
Connected Entities
Sources
www.govinfo.gov
Analysis Score
0–100- Significance90How much this matters to a regular citizen
- Controversy60Intensity of disagreement among stakeholders
- Entertainment20Compellingness for a non-policy-wonk reader
- Buzz75Current news / social attention level
Publisher tools